Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc.

INSP
Inspire Medical Systems, Inc.US flagNew York Stock Exchange
46.95
USD
+1.49
- -
1.35BMarket Cap
Inspire Medical Systems, Inc.
INSP
(New York Stock Exchange)

Recent

price

46.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.64
1.32
2.12
3.47
3.45
4.43
8.56
14.53
21.32
26.97
31.05
31.43
Revenue per Share
-1.71
-1.49
-1.3
-1.5
-1.4
-2.19
-1.54
-1.6
-0.72
1.8
4.95
4.5
Basic EPS, GAAP
-1.81
-1.46
-1.2
-1.3
-1.49
-2.13
-0.91
0.09
0.03
3.06
2.67
3.66
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-8.63
-9.27
-10.07
-7.57
-9.1
-10.25
-11.55
-11.79
-9.81
-4.99
-5.42
Book Value per Share
- -
-8.08
-8.73
11.25
5.87
8.81
8.4
17.67
19.54
23.17
26.6
27.21
Tangible Book Value per Share
12
12
13
15
24
26
27
28
29
30
29
29
Basic Weighted Avg Shares
8
16
29
51
82
115
233
408
625
803
912
915
Sales/Revenue/Turnover
-247.1
-105.03
-56.02
-40.28
-42.53
-48.72
-17.07
-11.67
-6.45
4.49
5.59
5.61
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
2
3
7
14
16
Depreciation Expense
-21
-19
-18
-22
-33
-57
-42
-45
-21
54
145
131
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.46
- -
597.88
Effective Tax Rate (%)
-266.31
-112.79
-61.3
-43.14
-40.52
-49.58
-18.01
-11
-3.39
6.67
15.95
14.33
Profit Margin (%)
- -
5
17
188
154
249
227
469
516
542
488
477
Working Capital
- -
12
16
25
25
31
25
8
25
30
30
30
LT Debt
- -
-7
1
164
140
230
229
496
573
690
781
792
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.01
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-18.44
- -
-84.04
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
30
30
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
2,196
2,709
1,502

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
586
584
567
Cash, Cash Equivalents & STI
323
308
284
Accounts Receivable, Net
108
120
105
Inventories
142
145
166
Total Current Liabilities
111
96
89
Payables & Accruals
109
94
89
ST Debt
2
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
33.08%
13.26%
Free Cash Flow
869.12%
1,712.19%
-13.88%
Net Income, GAAP
-12.34%
-50.76%
171.77%
Sales/Revenue/Turnover
63.11%
54.46%
13.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
164
196
203
240
803
2025
201
217
225
269
912
2026
205
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
0.33
0.62
1.18
1.8
2025
0.1
-0.12
0.34
4.7
4.95
2026
-0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes the Inspire therapy, an implantable neurostimulation system designed to treat moderate to severe obstructive sleep apnea (OSA) in adult patients unable to use or get consistent benefit from continuous positive airway pressure (CPAP) devices. The company's core products and services include the Inspire Upper Airway Stimulation (UAS) system, consisting of the Inspire implantable pulse generator (IPG), stimulation lead, sensing lead, and external patient remote control; surgical tools and accessories for implantation; the myInspire patient management platform for remote monitoring and therapy adjustments; and physician and patient education programs supporting therapy adoption. Inspire therapy offers a masked volume reduction alternative to CPAP, with implantation performed by ENTs and sleep surgeons in outpatient procedures; the company provides direct-to-consumer marketing, reimbursement support services, and post-market clinical research through its registry studies. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire Medical Systems operates primarily in the United States, with expanding commercial presence in Europe (including select countries via partnerships) and international markets targeting adult OSA patients underserved by traditional therapies. The company serves sleep clinics, ENT practices, hospitals, and sleep surgeons as key customers, focusing on the medical device segment of the sleep health industry valued at billions annually. In recent developments, Inspire Medical Systems reported strong revenue growth in 2025, driven by increased procedure volumes and market adoption; the company expanded its European operations through new regulatory approvals and partnerships in 2024-2025. It launched enhancements to the Inspire therapy platform, including software updates for improved therapy titration and remote monitoring capabilities; additionally, Inspire announced positive results from ongoing post-market studies demonstrating long-term efficacy and safety, supporting expanded indications. No major acquisitions, funding rounds, or name changes were reported in the last 1-2 years, with strategic focus remaining on U.S. market penetration and international scaling.

Company News

APIChatGPT
  • Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP

  • Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript

  • INSP Highlights New OSA Data and PREDICTOR Study at SLEEP 2026

  • Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study

  • Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight

  • Alphatec vs. Inspire Medical Systems: Which Healthcare Stock Is a Better Buy in 2026?

  • Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff

  • Why Is Inspire (INSP) Down 15.9% Since Last Earnings Report?

  • Inspire Medical Systems, Inc. (INSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Inspire: Why I'm Still Rating The Stock A 'Sell' After The Earnings Dip

  • Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down

  • Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, Devon Energy, GoDaddy, Home Depot, Lam Research, Lowe’s, Roblox, Tractor Supply, Ulta Beauty, and More

  • Inspire Medical Systems, Inc. (INSP) Q1 2026 Earnings Call Transcript

  • Inspire (INSP) Reports Q1 Earnings: What Key Metrics Have to Say

  • Inspire Medical Systems (INSP) Q1 Earnings and Revenues Top Estimates

  • Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance

  • Inspire Medical Systems, Inc. to Present at the BofA Securities 2026 Healthcare Conference

  • Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

  • Analysts Estimate Inspire Medical Systems (INSP) to Report a Decline in Earnings: What to Look Out for

  • These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar